Clinical trial · Observational
Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
Evaluation of the Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of \< 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Solid Tumors | Childhood Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Retrospective description of the clinical and therapeutic impact of the systematic performance of molecular analyzes on solid tumors
- timeFrame
- up to 12 months
- description
- The aim of this retrospective study is to improve and harmonize international practices
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 22 Years
Show eligibility criteria text
Inclusion criteria * Patients of pediatric age up to 22 years included at the time of molecular analysis * Histological carcinological diagnosis performed at HUS * Carcinological follow-up performed at HUS * Patients with a solid tumor of unfavorable prognosis, refractory or in relapse * Molecular analysis performed on tumor or blood samples * Adult patients who do not object to the re-use of their personal data for medical research purposes * Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes. Criteria for non-inclusion * Molecular biology results not usable due to poor sample quality or insufficient genetic material * Patients who have expressed their opposition to participate in the study * Parental authority holders who have expressed their opposition to participate in the study
References
Publications (0)
Data not yet available